Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic
April 06 2020 - 6:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today
announced that it is donating personal protective equipment to San
Diego’s Scripps Health for distribution to its front-line doctors,
nurses and other health-care practitioners caring for patients
affected by the COVID-19 pandemic.
The Company said that it has tapped its own medical supplies to
deliver 250 surgical face masks directly to Scripps Health, which
has an immediate and critical need for the protective gear for its
health care professionals. Scripps Health is a private,
nonprofit integrated health care system in San Diego. Plus
Therapeutics has had a longtime presence in San Diego.
“As a company dedicated to health care, we recognize the need to
assist the Scripps Health medical community, which is going above
and beyond the call of duty right now,” said Dr. Marc Hedrick,
President and Chief Executive Officer of Plus Therapeutics. “The
COVID-19 pandemic has few precedents in modern times, but we
understand that defeating this virus requires the support of
medical professionals and first responders at leading institutions
like Scripps Health.” About Plus Therapeutics,
Inc.
Plus Therapeutics is a clinical-stage pharmaceutical company
focused on making a positive impact on patients’ lives and adding
value to the healthcare system. We are a publicly-traded company on
Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters
in Austin, Texas and GMP-validated manufacturing facilities in San
Antonio, Texas. The location of our operations provides us
with many potential strategic advantages, including proximity to
world-class cancer institutions and researchers and the ability to
qualify and apply for funding through the Cancer Prevention and
Research Institute of Texas, or CPRIT.
We have two lead drug product candidates in our pipeline, RNL™
and DocePLUS™, being developed in the U.S. by a dedicated and
energetic team of biologists, chemists, engineers, physicians, and
other professionals. This diverse and experienced team is
using our proprietary and versatile nanotechnology platform to
reformulate and deliver approved chemotherapeutics and widely-used
radiotherapeutics to provide meaningful benefits to patients and
healthcare providers. The platform also serves as the
foundation and affords us the opportunity in the future to develop
additional drugs for rare cancers. More information may be found at
www.plustherapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements that may be
deemed “forward-looking statements” within the meaning of U.S.
securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Plus Therapeutics, Inc. Andrew Sims VP –
Chief Financial Officer, Investor Relations Phone: +1.619.333.4150
Email: ir@plustherapeutics.com
Website: plustherapeutics.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2024 to May 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From May 2023 to May 2024